This announcement was made alongside the reveal of positive Phase 3 results for Tanruprubart, a monoclonal antibody that can block C1q and can potentially halt neuroinflammation and nerve damage in ...

The newly approved prefilled syringe for self-injection of Vyvgart Hytrulo will provide more convenience and flexibility for ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...

Aims Guillain-Barré syndrome (GBS) is an autoimmune acute inflammatory polyradiculoneuropathy. Intravenous immunoglobulins (IVIG) are usually the first choice of treatment. At present, limited ...